Broadly neutralising antibodies in post-treatment control

Affiliations

¹ Division of Infectious Diseases, Department of Internal Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands. Electronic address: g.j.debree@amc.uva.nl.
² Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, USA.

Comment

Godelieve J de Bree et al. Lancet HIV. 2019 May.

. 2019 May;6(5):e271-e272.

doi: 10.1016/S2352-3018(19)30075-X. Epub 2019 Apr 15.

¹ Division of Infectious Diseases, Department of Internal Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands. Electronic address: g.j.debree@amc.uva.nl.
² Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, USA.

No abstract available

Comment on

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group. Crowell TA, et al. Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15. Lancet HIV. 2019. PMID: 31000477 Free PMC article. Clinical Trial.